行情

TTPH

TTPH

Tetraphase制药
NASDAQ

实时行情|Nasdaq Last Sale

1.830
-0.210
-10.29%
盘后: 1.860 +0.03 +1.64% 16:30 02/27 EST
开盘
2.020
昨收
2.040
最高
2.020
最低
1.810
成交量
17.84万
成交额
--
52周最高
29.00
52周最低
1.810
市值
1,069.85万
市盈率(TTM)
-0.0616
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测TTPH价格均价为1.500,最高价位1.500,最低价为1.500。

EPS

TTPH 新闻

更多
  • The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
  • Benzinga · 1天前
  • Benzinga's Top Upgrades, Downgrades For January 24, 2020
  • Benzinga · 01/24 14:57
  • RBC likes BioMarin in premarket analyst action
  • Seeking Alpha - Article · 01/24 12:31
  • Gabelli & Co. Downgrades Tetraphase Pharmaceutical to Hold
  • Benzinga · 01/24 12:23

所属板块

制药
-2.87%
制药与医学研究
-2.83%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

TTPH 简况

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
展开

微牛提供Tetraphase Pharmaceuticals Inc(NASDAQ-TTPH)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的TTPH股票新闻,以帮助您做出投资决策。